As GLP-1 drugs go mainstream, this expert says health is more than a number on a scaleAs GLP-1 drugs go mainstream, this expert says health is more than a number on a scale
Popular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump administration and two major drugmakers announced an agreement to drastically reduce the cost of the drugs for people enrolled in Medicare and Medicaid, as well as for cash buyers. Popular weight-loss drugs known as GLP-1s could soon become Read More
Wegovy and Ozempic tied to dramatically lower cancer deathsWegovy and Ozempic tied to dramatically lower cancer deaths
GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to Read More
Year in Review: Breast CancerYear in Review: Breast Cancer
(MedPage Today) — Despite tremendous advances in diagnosis, treatment, and survival, breast cancer remains the most common type of cancer in the U.S., with an estimated 317,000 new cases in 2025. The disease burden drives the search for ways to…
Ozempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes DiagnosesOzempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes Diagnoses
(MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic formulation of semaglutide appears in Google searches for weight loss, despite not being FDA-approved for this indication. (NPR) New analyses… (MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic Read More
T-DXd Moves Into Curative Setting in HER2-Positive Breast CancerT-DXd Moves Into Curative Setting in HER2-Positive Breast Cancer
(MedPage Today) — The DESTINY-Breast11 (DB-11) and DESTINY-Breast05 (DB-05) trials, presented at the European Society for Medical Oncology (ESMO) congress, showed that the inclusion of neoadjuvant or adjuvant trastuzumab pathologic complete response…
Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis TargetInvestigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target
(MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve… (MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening Read More
GLP-1 drugs linked to dramatically lower death rates in colon cancer patientsGLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that Read More
Common Everyday Meds Linked to Worse Outcomes in Breast Cancer PatientsCommon Everyday Meds Linked to Worse Outcomes in Breast Cancer Patients
(MedPage Today) — Use of proton pump inhibitors (PPIs) alongside anti-cancer agents was associated with worse survival outcomes in patients with breast cancer, according to an observational study.
Using pooled patient data from 19 breast cancer…
Semaglutide’s MASH Benefits Extend Beyond Weight LossSemaglutide’s MASH Benefits Extend Beyond Weight Loss
(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according… (MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological Read More
Weight loss drug could help avoid need for follow-up bariatric surgeryWeight loss drug could help avoid need for follow-up bariatric surgery
Combining bariatric surgery with weight loss medication can help people who need to lose more weight post-surgery, Monash University and Alfred Health-led research has found.